Product Certification&
    Enterprise Certification

  • Mr.Jack
    Tel: +86-28-85337952

  • Mobile:+86-18244224145
  • Tel:+86-28-85337952
  • Fax:+86-28-85337952
  • Province/state:Sichuan
  • City:Chengdu
  • Street:1-B-26,Tianhe Industry Park, No.1480 of Tianfu Road,Chengdu,P.R.China,610000
  • MaxCard:
Home > Products >  3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline

3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline CAS NO.641571-11-1

  • FOB Price: USD: 480.00-500.00 /Kilogram Get Latest Price
  • Min.Order: 1 Gram
  • Payment Terms: L/C,D/A,D/P,T/T,Other
  • Available Specifications:

    A(1-10)KilogramA(10-100)Kilogram

  • Product Details

Keywords

  • 3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline
  • 641571-11-1

Quick Details

  • ProName: 3-(4-Methyl-1H-imidazol-1-yl)-5-(trifl...
  • CasNo: 641571-11-1
  • Molecular Formula: C11H10F3N3
  • Appearance: White Powder
  • Application: intermediate for Erlotinib
  • DeliveryTime: Min 3 Days
  • PackAge: Bag/Drum
  • Port: Chengdu
  • ProductionCapacity: 1 Metric Ton/Day
  • Purity: 99.0%
  • Storage: In Cool Place
  • Transportation: Air/Sea
  • LimitNum: 1 Gram

Superiority

We specialized in APIS/ Intermediates and Focus on Technical more than 10 years.we have a perfect research and development technology and manufacturing. We have more advantages of technical and price.
 

Details

 Nilotinib (AMN107, trade name Tasigna), in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor approved for the treatment of chronic myelogenous leukemia.

 

Nilotinib was approved as Tasigna in the USA and the EU for drug-resistant chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (trade name:Gleevec [USA]/ Glivec [Europe/Australia/Latin America]), another tyrosine kinase inhibitor currently used as a first-line treatment. In that study 92% of patients (already resistant or unresponsive to imatinib) achieved a normal white blood cell counts after five months of treatment.The drug carries a black box warning for possible heart complications.The use of low doses of nilotinib is being investigated for use for Parkinson's and Alzheimer's disease, as well as for ALSdementiaand Huntington's disease.

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog